Handok said Wednesday that it has agreed with Sanofi Pasteur to co-promote six of the latter’s vaccines.
|Handok CEO Kim Young-jin (right) and Sanofi Pasteur Korea CEO Baptiste de Clarens shake hands after signing an agreement, at Sanofi Pasteur Korea headquarters in Seocho-gu, southern Seoul, on Tuesday.|
The six new vaccines are Avaxim 160U Adult Inj. (Hepatitis A vaccine), Adacel Inj. (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine), Menactra Inj. (meningitis vaccine), Imojev Inj. (Japanese encephalitis vaccine), Pentaxim Inj. (polio, pertussis and haemophilus influenza type B vaccine) and Tetraxim Inj. (diphtheria, tetanus, pertussis /acellular, component/ and inactivated poliomyelitis adsorbed vaccine).
With the accord, Handok is responsible for marketing eight of Sanofi’s vaccines, including the previously signed Vaxigriptetra Inj. (quadrivalent influenza vaccine) and Vaxigrip Inj. (trivalent influenza vaccine).
“We are pleased to strengthen cooperation with Sanofi Pasteur and take on a broader range of vaccines as the number of patients with hepatitis A is increasing, and interest in vaccination is rising,” Handok CEO Kim Young-jin said. “We will continue to do our best to provide good vaccine to the domestic market.”
Sanofi Pasteur Korea CEO Baptiste de Clarens also said, “We expect this partnership will enhance business efficiency and create synergies by combining strengths of both companies.”
<© Korea Biomedical Review, All rights reserved.>